CN115677730B - 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途 - Google Patents

8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途 Download PDF

Info

Publication number
CN115677730B
CN115677730B CN202210884665.8A CN202210884665A CN115677730B CN 115677730 B CN115677730 B CN 115677730B CN 202210884665 A CN202210884665 A CN 202210884665A CN 115677730 B CN115677730 B CN 115677730B
Authority
CN
China
Prior art keywords
compound
mmol
formula
azabicyclo
oxa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210884665.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN115677730A (zh
Inventor
程耀邦
黄亚飞
周娟
王永辉
陈伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lidi Hangzhou Pharmaceutical Technology Co ltd
Original Assignee
Lidi Hangzhou Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lidi Hangzhou Pharmaceutical Technology Co ltd filed Critical Lidi Hangzhou Pharmaceutical Technology Co ltd
Publication of CN115677730A publication Critical patent/CN115677730A/zh
Application granted granted Critical
Publication of CN115677730B publication Critical patent/CN115677730B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202210884665.8A 2021-07-27 2022-07-26 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途 Active CN115677730B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202110860428 2021-07-27
CN2021108604283 2021-07-27
CN2022107793028 2022-07-01
CN202210779302 2022-07-01

Publications (2)

Publication Number Publication Date
CN115677730A CN115677730A (zh) 2023-02-03
CN115677730B true CN115677730B (zh) 2024-11-12

Family

ID=85060847

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210884665.8A Active CN115677730B (zh) 2021-07-27 2022-07-26 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途
CN202280052257.4A Pending CN118043325A (zh) 2021-07-27 2022-07-26 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202280052257.4A Pending CN118043325A (zh) 2021-07-27 2022-07-26 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途

Country Status (10)

Country Link
US (1) US20240294550A1 (https=)
EP (1) EP4378943A4 (https=)
JP (1) JP2024527044A (https=)
KR (1) KR20240041354A (https=)
CN (2) CN115677730B (https=)
AU (1) AU2022316931A1 (https=)
CA (1) CA3227713A1 (https=)
IL (1) IL310412A (https=)
TW (1) TW202321256A (https=)
WO (1) WO2023005928A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202602891A (zh) * 2024-03-28 2026-01-16 大陸商勵締（杭州）醫藥科技有限公司 具有mTOR抑制活性的有機化合物及其用途
TW202545519A (zh) * 2024-05-15 2025-12-01 俄羅斯聯邦商拜奧卡德聯合股份公司 共濟失調毛細血管擴張症和Ｒａｄ３相關激酶抑制劑
WO2026037494A1 (en) * 2024-08-14 2026-02-19 Eracal Therapeutics Ltd. New compounds and their uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022028598A1 (en) * 2020-08-07 2022-02-10 Shanghai Antengene Corporation Limited Atr inhibitors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI700283B (zh) 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
CN109071565B (zh) 2016-05-24 2022-05-10 默克专利股份公司 三环杂环衍生物
IL281212B2 (en) 2018-09-07 2023-12-01 Merck Patent Gmbh 5-Morpholin-4-yl-pyrazolo[4,3-B]pyridine derivatives and their use
CR20210281A (es) 2018-10-30 2021-10-25 Repare Therapeutics Inc Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr
CN111848605B (zh) 2019-04-30 2023-05-02 四川科伦博泰生物医药股份有限公司 一种取代吡啶并[3,4-b]吡嗪-2(1H)-酮化合物、其制备方法和用途
CN112142744A (zh) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
MX2022000854A (es) * 2019-07-22 2022-02-10 Repare Therapeutics Inc Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022028598A1 (en) * 2020-08-07 2022-02-10 Shanghai Antengene Corporation Limited Atr inhibitors and uses thereof

Also Published As

Publication number Publication date
JP2024527044A (ja) 2024-07-19
WO2023005928A1 (zh) 2023-02-02
EP4378943A1 (en) 2024-06-05
TW202321256A (zh) 2023-06-01
EP4378943A4 (en) 2024-12-11
CA3227713A1 (en) 2023-02-02
AU2022316931A1 (en) 2024-03-14
CN115677730A (zh) 2023-02-03
US20240294550A1 (en) 2024-09-05
KR20240041354A (ko) 2024-03-29
IL310412A (en) 2024-03-01
CN118043325A (zh) 2024-05-14

Similar Documents

Publication Publication Date Title
CN112300173B (zh) 一类含氮多环类化合物、制备方法和用途
CN108699062B (zh) 四氢吡喃基氨基-吡咯并嘧啶酮及其使用方法
JP6457623B2 (ja) ２，４−二置換７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体、その製造方法および医薬における使用
CN115677730B (zh) 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途
AU2014225155B2 (en) Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof
KR20170069199A (ko) 섬유 아세포 성장 인자 수용체 키나아제 억제제인 인다졸계 화합물 및 이의 제조와 응용
CN101932584A (zh) 作为pi3k阻滞剂的吡咯并嘧啶衍生物及其用途
CN109721600B (zh) 一类含氮稠环化合物及其制备方法和用途
WO2021126923A1 (en) Cd206 modulators their use and methods for preparation
US20180346467A9 (en) Preparation and use of kinase inhibitor
CN116375712A (zh) 双吗啉取代的杂环化合物及其医药用途
JP7110335B2 (ja) プロテインキナーゼ阻害剤として有用なピリドキナゾリン誘導体
JP2022528437A (ja) ピペラジンアミド誘導体、その製造方法及び医薬におけるその用途
EA050883B1 (ru) 8-окса-3-азабицикло[3.2.1]октановые соединения или их соли, способ их получения и применение
CN113150012B (zh) 吡唑并[1,5-a]吡嗪类衍生物及其制备方法和用途
JPWO2023005928A5 (https=)
US20250092052A1 (en) Heteroaryl derivative compounds, and uses thereof
HK40082693B (zh) 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途
HK40082693A (en) 8-oxo-3-azabicyclo[3.2.1]octane compounds or salts thereof, and preparation method and use thereof
TWI750645B (zh) 四氫哌喃基胺基-吡咯並嘧啶酮和使用彼之方法
TW202604908A (zh) 雜環化合物及其作為ｒｅｔ抑制劑的用途
JP2024510520A (ja) ダブルリング雑環ｆｇｆｒ４阻害剤、ダブルリング雑環ｆｇｆｒ４阻害剤を含有する医薬組成物と製剤、及びその用途
AU2023404413A1 (en) Compounds for modulating hur (elavl1)
WO2025218778A9 (zh) 杂环化合物及其作为ret抑制剂的用途
WO2023083373A1 (zh) 作为Src抑制剂的化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40082693

Country of ref document: HK

CB02 Change of applicant information

Address after: Room 401, Building 4, No. 88 Jiangling Road, Xixing Street, Binjiang District, Hangzhou City, Zhejiang Province, 310051

Applicant after: Lidi (Hangzhou) Pharmaceutical Technology Co.,Ltd.

Address before: Room 1109, 781 Cailun Road, Pudong New Area, Shanghai 201203

Applicant before: Shanghai Huiqi Biomedical Technology Co.,Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant